Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology.

Kleinjan A, Böing AN, Sturk A, Nieuwland R.

Thromb Res. 2012 Oct;130 Suppl 1:S71-3. doi: 10.1016/j.thromres.2012.08.281. Review.

2.

Cell-derived vesicles exposing coagulant tissue factor in saliva.

Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R.

Blood. 2011 Mar 17;117(11):3172-80. doi: 10.1182/blood-2010-06-290460. Epub 2011 Jan 19.

3.

Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.

Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S, Simioni P.

Thromb Res. 2011 May;127(5):473-7. doi: 10.1016/j.thromres.2011.01.002. Epub 2011 Jan 22.

PMID:
21256535
4.

Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.

Geddings JE, Mackman N.

Blood. 2013 Sep 12;122(11):1873-80. doi: 10.1182/blood-2013-04-460139. Epub 2013 Jun 24. Review.

5.

Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.

Sartori MT, Della Puppa A, Ballin A, Campello E, Radu CM, Saggiorato G, d'Avella D, Scienza R, Cella G, Simioni P.

Thromb Haemost. 2013 Aug;110(2):378-85. doi: 10.1160/TH12-12-0957. Epub 2013 Jun 27.

PMID:
23803674
6.

Microvesicles as risk markers for venous thrombosis.

Rautou PE, Mackman N.

Expert Rev Hematol. 2013 Feb;6(1):91-101. doi: 10.1586/ehm.12.74. Review.

PMID:
23373784
7.

Microparticles and cancer thrombosis in animal models.

Mege D, Mezouar S, Dignat-George F, Panicot-Dubois L, Dubois C.

Thromb Res. 2016 Apr;140 Suppl 1:S21-6. doi: 10.1016/S0049-3848(16)30094-9. Review.

PMID:
27067974
8.

Clinical Significance of Tissue Factor-Exposing Microparticles in Arterial and Venous Thrombosis.

van Es N, Bleker S, Sturk A, Nieuwland R.

Semin Thromb Hemost. 2015 Oct;41(7):718-27. doi: 10.1055/s-0035-1556047. Epub 2015 Sep 26. Review.

PMID:
26408926
9.

Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine.

Yates KR, Welsh J, Echrish HH, Greenman J, Maraveyas A, Madden LA.

Blood Coagul Fibrinolysis. 2011 Dec;22(8):680-7. doi: 10.1097/MBC.0b013e32834ad7bc.

PMID:
21941170
10.

Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays.

Hisada Y, Alexander W, Kasthuri R, Voorhees P, Mobarrez F, Taylor A, McNamara C, Wallen H, Witkowski M, Key NS, Rauch U, Mackman N.

Thromb Res. 2016 Mar;139:90-7. doi: 10.1016/j.thromres.2016.01.011. Epub 2016 Jan 18. Review.

PMID:
26916302
11.

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.

Haubold K, Rink M, Spath B, Friedrich M, Chun FK, Marx G, Amirkhosravi A, Francis JL, Bokemeyer C, Eifrig B, Langer F.

Thromb Haemost. 2009 Jun;101(6):1147-55.

PMID:
19492160
12.

Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients.

Hernández C, Orbe J, Roncal C, Alvarez-Hernandez M, Martinez de Lizarrondo S, Alves MT, García Mata J, Páramo JA.

Thromb Haemost. 2013 Sep;110(3):598-608. doi: 10.1160/TH13-02-0122. Epub 2013 Jun 27.

PMID:
23803792
13.

Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty.

Johnson GJ, Leis LA, Bach RR.

Thromb Haemost. 2009 Oct;102(4):728-34. doi: 10.1160/TH09-04-0261.

PMID:
19806259
14.

Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.

van Doormaal F, Kleinjan A, Berckmans RJ, Mackman N, Manly D, Kamphuisen PW, Richel DJ, Büller HR, Sturk A, Nieuwland R.

Thromb Haemost. 2012 Jul;108(1):160-5. doi: 10.1160/TH12-02-0099. Epub 2012 Apr 26.

PMID:
22535219
15.

Tissue factor-dependent blood coagulation is enhanced following delivery irrespective of the mode of delivery.

Boer K, den Hollander IA, Meijers JC, Levi M.

J Thromb Haemost. 2007 Dec;5(12):2415-20. Epub 2007 Sep 19.

16.

Tissue factor: (patho)physiology and cellular biology.

Eilertsen KE, Østerud B.

Blood Coagul Fibrinolysis. 2004 Oct;15(7):521-38. Review.

PMID:
15389118
17.

Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.

Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, Brümmendorf TH, Dierlamm J, Bokemeyer C, Eifrig B.

Ann Hematol. 2008 Jun;87(6):451-7. doi: 10.1007/s00277-008-0446-3. Epub 2008 Feb 22.

PMID:
18292996
18.

Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers.

Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, Iyer RV.

Thromb Res. 2013 Aug;132(2):180-4. doi: 10.1016/j.thromres.2013.06.026. Epub 2013 Jul 13.

PMID:
23856554
19.

Tumour and microparticle tissue factor expression and cancer thrombosis.

Date K, Hall J, Greenman J, Maraveyas A, Madden LA.

Thromb Res. 2013 Feb;131(2):109-15. doi: 10.1016/j.thromres.2012.11.013. Epub 2012 Dec 11. Review.

PMID:
23237339
20.

Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year.

Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T.

Thromb Res. 2014 Nov;134(5):1093-6. doi: 10.1016/j.thromres.2014.07.041. Epub 2014 Aug 22.

PMID:
25262106

Supplemental Content

Support Center